Article

Enrollment complete for trial of trabeculoplasty with titanium laser

Boston-Patient enrollment in a multicenter trial to study trabeculoplasty performed with a titanium-sapphire laser (SOLX 790, OccuLogix) is complete, according to the laser’s manufacturer.

Boston-Patient enrollment in a multicenter trial to study trabeculoplasty performed with a titanium-sapphire laser (SOLX 790, OccuLogix) is complete, according to the laser’s manufacturer. The research is being conducted in more than 160 eyes in an effort to obtain 510(k) clearance from the FDA.

Enrollees are patients with primary open-angle glaucoma in eyes with poorly controlled IOP on maximally tolerated medications and/or prior failed glaucoma surgery. Patients were randomly assigned to undergo outpatient treatment with the titanium-sapphire laser or with an argon laser. Each group contains a similar number of eyes, and each of the investigational sites-in the United States, Canada, Israel, and Spain-has a similar number of eyes enrolled. Preliminary review of the data shows consistent, equivalent IOP reduction in patients in both groups followed for up to 1 year, according to the company.

“This laser is the first of its kind to use the 790-nm wavelength, which has been shown to penetrate the tissue deeper than other laser trabeculoplasty procedures while preserving the integrity of the trabecular meshwork,” said Doug Adams, chief executive officer and founder of SOLX, the glaucoma division of OccuLogix.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.